Zimmer Biomet Holdings Inc. ZBH, -4.67% that ZimVie Inc., the wholly owned subsidiary that is being spun off into a separate, publicly traded company will have $1.0 billion in revenue in 2022, which will be about the same as 2021. ZimVie, which is expected to begin trading as a standalone entity on March 1, is also expected to have adjusted earnings per share of $2.10 to $2.30 in 2022. Zimmer Biomet had announced in February 2021 it’s intent to spin off its spine and dental businesses. The company said it will retain 19.7% of the outstanding shares of ZimView once it goes public. Zimmer shares, which shed 4.4% in morning trading, have tumbled 17.1% over the past three months, while the S&P 500 SPX, +0.18% has eased 3.9%.
